Quantum Genomics (ALQGC.PA)

Executive Summary

Quantum Genomics is a French biopharmaceutical company focused on developing first-in-class oral small molecule inhibitors targeting the brain aminopeptidase A (APA) pathway for resistant hypertension and heart failure. Its lead candidate, firibastat, has demonstrated proof-of-concept in Phase 2 trials and is currently advancing toward pivotal studies. The company's approach is unique in acting centrally within the brain to regulate blood pressure, potentially offering a novel mechanism for patients who do not respond to existing therapies. With a small market capitalization of approximately €5 million, Quantum Genomics represents a high-risk, high-reward opportunity dependent on successful clinical development and potential partnership or licensing deals. The limited pipeline and reliance on firibastat make the company vulnerable to trial outcomes, but if successful, firibastat could address a significant unmet need in resistant hypertension. The company's near-term focus is on advancing firibastat through Phase 3 trials and securing regulatory interactions to define the path forward.

Upcoming Catalysts (preview)

• Q4 2026Phase 2b/3 clinical trial results for firibastat in resistant hypertension30% success
• Q2 2026Regulatory guidance or end-of-Phase 2 meeting outcomes60% success
• H2 2026Potential partnership or licensing deal for firibastat20% success